Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition
admin 17th July 2019 Uncategorised 0AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. More: Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition Source: News
read more